IMCR — Immunocore Holdings plc

Why people talked about IMCR (2026-11-07)

• Immunocore reported Q3 2026 KIMMTRAK net revenues of $102.2 million, missing EPS estimates by $0.15.
• The company presented promising Phase 1/2 trial data showing a 70% estimated two-year survival rate for brenetafusp plus KIMMTRAK in metastatic uveal melanoma.
• Q3 net loss widened to $14.2 million due to increased R&D expenses, despite underlying revenue growth of approximately 10%.